Abstract
Cardiovascular disease is the leading cause of death in patients receiving hemodialysis. Currently there is no standardized definition of myocardial infarction (MI) for patients receiving hemodialysis. Through an international consensus process MI was established as the core CVD measure for this population in clinical trials. The Standardised Outcomes in Nephrology Group – Hemodialysis (SONG-HD) initiative convened a multidisciplinary, international working group to address the definition of MI in this population. Based on current evidence, the working group recommends using the 4th Universal Definition of MI with specific caveats with regard to the interpretation of “ischemic symptoms” and performing a baseline 12-lead electrocardiogram to facilitate interpretation of acute changes on subsequent tracings. The working group do not recommend obtaining baseline cardiac troponin values, nor do we recommend obtaining serial cardiac biomarkers in settings where ischemia is suspected. Application of an evidence-based uniform definition should increase the reliability and accuracy of trial results.
| Original language | English |
|---|---|
| Pages (from-to) | 1028-1037 |
| Number of pages | 10 |
| Journal | Kidney International |
| Volume | 103 |
| Issue number | 6 |
| Early online date | 5 Apr 2023 |
| DOIs | |
| Publication status | E-pub ahead of print - 5 Apr 2023 |
Bibliographical note
Funding Information:We thank Kimberly Smith and Aliza Thompson from the Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research (CDER), United States Food and Drug Administration, who attended and contributed to the consensus workshop, and David Charytan, who reviewed the manuscript. This work was supported by the National Health and Medical Research Council Australia (NHMRC; 1098815 ).
Funding Information:
We thank Kimberly Smith and Aliza Thompson from the Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research (CDER), United States Food and Drug Administration, who attended and contributed to the consensus workshop, and David Charytan, who reviewed the manuscript. This work was supported by the National Health and Medical Research Council Australia (NHMRC; 1098815).
Publisher Copyright:
© 2023 International Society of Nephrology
Access to Document
- Full-text PDF (accepted manuscript)
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/j.kint.2023.02.033. Please refer to any applicable terms of use of the publisher.